IL6 and type 2 diabetes mellitus: In this study, individual treatments with complete and truncated forms of NLL β-conglutin proteins (β5 and β7), applied to LPS-stimulated in vitro (HepG2) model culture cells and ex vivo (isolate PBMC from blood samples of T2D-diagnosed patients and healthy control subjects) assays, decreased mRNA expression of key pro-inflammatory molecules in T2D, including IL-1β, IL-2, IL-6, IL-8, IL-12, IL-17, IL-27, INF-γ, MOP, S-TNF-R1/-R2, TWEAK, TNF-α, and iNOS gene expression and NO production.